PMID- 16644117
OWN - NLM
STAT- MEDLINE
DCOM- 20070116
LR  - 20131121
IS  - 0304-3940 (Print)
IS  - 0304-3940 (Linking)
VI  - 402
IP  - 1-2
DP  - 2006 Jul 10
TI  - Differential effects of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") on 
      BDNF mRNA expression in rat frontal cortex and hippocampus.
PG  - 126-30
AB  - The serotonergic neurotoxin 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") 
      produces rapid serotonin (5-HT) depletion in different areas of the forebrain 
      after acute administration to rats and other animal species. We previously found 
      that 5-HT depletion induced by acute MDMA treatment was transient in the frontal 
      cortex, but not in the hippocampus, and recovery of cortical 5-HT levels 
      correlated with an induction of CRE-binding activity and increased expression of 
      tryptophan-hydroxylase (TPH), the rate-limiting enzyme in 5-HT biosynthesis. As 
      the brain-derived neurotrophic factor (BDNF) stimulates the growth and sprouting 
      of serotonergic neurons, we sought the possible involvement of this neurotrophin 
      in the region-specific increase in TPH mRNA expression induced by MDMA. We here 
      report that, 24-48 h after acute MDMA treatment, the expression of BDNF in the 
      frontal cortex is increased by approximately 33-70%, and the levels of the 
      transcription factor phospho-CREB are also increased. In the hippocampus, 
      however, a time-dependent decrease in BDNF mRNA expression (maximal decrease of 
      approximately 73%) is found in all subfields examined 2-7 days after treatment in 
      spite of increased phospho-CREB levels, perhaps as a consequence of 
      corticosterone release by the serotonergic neurotoxin. The differential 
      regulation of BDNF mRNA expression in the two brain regions examined appears to 
      account for the enhanced TPH expression and the recovery of 5-HT levels in the 
      frontal cortex, but not in the hippocampus, after neurotoxin treatment.
FAU - Martinez-Turrillas, Rebeca
AU  - Martinez-Turrillas R
AD  - Department of Pharmacology, School of Medicine, University of Navarra, Aptdo. 
      177, 31080-Pamplona, Spain.
FAU - Moyano, Sonia
AU  - Moyano S
FAU - Del Rio, Joaquin
AU  - Del Rio J
FAU - Frechilla, Diana
AU  - Frechilla D
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20060427
PL  - Ireland
TA  - Neurosci Lett
JT  - Neuroscience letters
JID - 7600130
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Hallucinogens)
RN  - 0 (RNA, Messenger)
RN  - 333DO1RDJY (Serotonin)
RN  - EC 1.14.16.4 (Tryptophan Hydroxylase)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Analysis of Variance
MH  - Animals
MH  - Brain-Derived Neurotrophic Factor/genetics/*metabolism
MH  - Frontal Lobe/*drug effects
MH  - Gene Expression/*drug effects
MH  - Hallucinogens/*pharmacology
MH  - Hippocampus/*drug effects
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*pharmacology
MH  - RNA, Messenger/metabolism
MH  - Rats
MH  - Rats, Wistar
MH  - Serotonin/metabolism
MH  - Time Factors
MH  - Tryptophan Hydroxylase/metabolism
EDAT- 2006/04/29 09:00
MHDA- 2007/01/17 09:00
CRDT- 2006/04/29 09:00
PHST- 2006/02/08 00:00 [received]
PHST- 2006/03/20 00:00 [revised]
PHST- 2006/03/24 00:00 [accepted]
PHST- 2006/04/29 09:00 [pubmed]
PHST- 2007/01/17 09:00 [medline]
PHST- 2006/04/29 09:00 [entrez]
AID - S0304-3940(06)00338-7 [pii]
AID - 10.1016/j.neulet.2006.03.055 [doi]
PST - ppublish
SO  - Neurosci Lett. 2006 Jul 10;402(1-2):126-30. doi: 10.1016/j.neulet.2006.03.055. 
      Epub 2006 Apr 27.